Answers are grounded in this paper and cite their sources.
The ability to control T cells engineered to permanently express chimeric antigen receptors (CARs) is a key feature to improve safety. Here, we describe the development of a new CAR architecture with an integrated switch-on system that permits to control the CAR T-cell function. This system offers the advantage of a transient CAR T-cell for safety while letting open the possibility of multiple cytotoxicity cycles using a small molecule drug.
No takes yet. Share an insight, caveat, or question.
Juillerat et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: